Education
About Us
Working with TipRanks
Follow Us
Perspective Therapeutics (CATX)
:CATX
CATX Analyst Ratings
Strong Buy
10 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
CATX Stock 12 Month Forecast
Average Price Target
$14.20
▲(545.45% Upside)
| Highest Price Target$21.00 | Average Price Target$14.20 | Lowest Price Target$6.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Bank of America Securities
Reiterated
03/28/25
Wedbush
Reiterated
03/27/25
Oppenheimer
Reiterated
03/27/25
LifeSci Capital
Reiterated
03/27/25
Scotiabank
Reiterated
03/27/25
RBC Capital
Reiterated
03/26/25
JonesTrading
Reiterated
03/26/25
H.C. Wainwright
Reiterated
03/18/25
Brookline Capital Markets
Initiated
03/10/25
Truist Financial
Assigned
01/27/25
Lucid Capital
$15→$20
Buy
809.09%
Upside
Reiterated
01/27/25
Perspective Therapeutics Inc (CATX) PT Raised to $20 at Lucid Capital MarketsLucid Capital Markets analyst Christopher Liu raised the price target on Perspective Therapeutics Inc (NYSE: CATX) to $20.00 (from $15.00) while maintaining a Buy rating.
B.Riley Financial
$17→$9
Buy
309.09%
Upside
Reiterated
11/26/24
Perspective Therapeutics price target lowered to $9 from $17 at B. RileyPerspective Therapeutics price target lowered to $9 from $17 at B. Riley
UBS
$20
Buy
809.09%
Upside
Initiated
10/24/24
Perspective Therapeutics initiated with a Buy at UBSPerspective Therapeutics initiated with a Buy at UBS
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Bank of America Securities
Reiterated
03/28/25
Wedbush
Reiterated
03/27/25
Oppenheimer
Reiterated
03/27/25
LifeSci Capital
Reiterated
03/27/25
Scotiabank
Reiterated
03/27/25
RBC Capital
Reiterated
03/26/25
JonesTrading
Reiterated
03/26/25
H.C. Wainwright
Reiterated
03/18/25
Brookline Capital Markets
Initiated
03/10/25
Truist Financial
Assigned
01/27/25
Lucid Capital
$15→$20
Buy
809.09%
Upside
Reiterated
01/27/25
Perspective Therapeutics Inc (CATX) PT Raised to $20 at Lucid Capital MarketsLucid Capital Markets analyst Christopher Liu raised the price target on Perspective Therapeutics Inc (NYSE: CATX) to $20.00 (from $15.00) while maintaining a Buy rating.
B.Riley Financial
$17→$9
Buy
309.09%
Upside
Reiterated
11/26/24
Perspective Therapeutics price target lowered to $9 from $17 at B. RileyPerspective Therapeutics price target lowered to $9 from $17 at B. Riley
UBS
$20
Buy
809.09%
Upside
Initiated
10/24/24
Perspective Therapeutics initiated with a Buy at UBSPerspective Therapeutics initiated with a Buy at UBS
CATX Analyst Recommendation Trends
Rating
Sep 24
Oct 24
Nov 24
Jan 25
Mar 25
Strong Buy
9
14
23
25
30
Buy
1
2
1
3
2
Hold
0
0
1
3
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
10
16
25
31
36
Each month's total comprises the sum of three months' worth of ratings.
CATX Financial Forecast
CATX Stock Forecast FAQ
What is CATX’s average 12-month price target, according to analysts?
Based on analyst ratings, Perspective Therapeutics’s 12-month average price target is $14.20.
What is CATX’s upside potential, based on the analysts’ average price target?
Perspective Therapeutics has 545.45% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CATX a Buy, Sell or Hold?
Perspective Therapeutics has a consensus rating of Strong Buy which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.
What is Perspective Therapeutics’s price target?
The average price target for Perspective Therapeutics is $14.20. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $21.00 ,the lowest forecast is $6.00. The average price target represents 545.45% Increase from the current price of $2.2.
The highest analyst price target is $21.00 ,the lowest forecast is $6.00. The average price target represents 545.45% Increase from the current price of $2.2.
What do analysts say about Perspective Therapeutics?
Perspective Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
How can I buy shares of CATX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.